TEL AVIV Mon Mar 24, 2014 12:07am EDT
<span id="articleText"/> TEL AVIV (Reuters) - Israel-based BrainStorm Cell Therapeutics said on Monday the U.S. Patent and Trademark Office has granted the company a key patent for its autologous stem cell technology.
<span id="midArticle_0"/> The patent covers BrainStorm's stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
<span id="midArticle_1"/> Pending approval from the U.S. Food & Drug Administration, the company is preparing for its upcoming mid-stage Phase II trial in the United States with its NurOwn adult stem cell therapy.
<span id="midArticle_2"/> BrainStorm is developing NurOwn for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
<span id="midArticle_3"/> Separately, the company said it has signed a definitive agreement with Massachusetts General Hospital in Boston to conduct a Phase II clinical trial of NurOwn in ALS, pending FDA approval. The other two clinical sites slated for the trial are the University of Massachusetts Memorial Hospital and Mayo Clinic.
<span id="midArticle_4"/> "The recent bill introduced to the U.S. Senate to support regenerative medicine research is yet another indication of the increasing recognition that stem cells hold the promise for curing life-threatening and debilitating conditions like ALS," said Chaim Lebovits, BrainStorm's president.
<span id="midArticle_5"/> "We are very encouraged by the bill's proposal to appoint a council that would develop and maintain a national strategy for the promotion of regenerative medicine research and development."
<span id="midArticle_6"/> (Reporting by Tova Cohen)
<span id="midArticle_7"/>
<span id="articleText"/> TEL AVIV (Reuters) - Israel-based BrainStorm Cell Therapeutics said on Monday the U.S. Patent and Trademark Office has granted the company a key patent for its autologous stem cell technology.
<span id="midArticle_0"/> The patent covers BrainStorm's stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
<span id="midArticle_1"/> Pending approval from the U.S. Food & Drug Administration, the company is preparing for its upcoming mid-stage Phase II trial in the United States with its NurOwn adult stem cell therapy.
<span id="midArticle_2"/> BrainStorm is developing NurOwn for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
<span id="midArticle_3"/> Separately, the company said it has signed a definitive agreement with Massachusetts General Hospital in Boston to conduct a Phase II clinical trial of NurOwn in ALS, pending FDA approval. The other two clinical sites slated for the trial are the University of Massachusetts Memorial Hospital and Mayo Clinic.
<span id="midArticle_4"/> "The recent bill introduced to the U.S. Senate to support regenerative medicine research is yet another indication of the increasing recognition that stem cells hold the promise for curing life-threatening and debilitating conditions like ALS," said Chaim Lebovits, BrainStorm's president.
<span id="midArticle_5"/> "We are very encouraged by the bill's proposal to appoint a council that would develop and maintain a national strategy for the promotion of regenerative medicine research and development."
<span id="midArticle_6"/> (Reporting by Tova Cohen)
<span id="midArticle_7"/>
- Link this
- Share this
- Digg this
- Reprints
via Smart Health Shop Forum http://ift.tt/1nTjZ1N
No comments:
Post a Comment